Eupatorin's Effects on Breast Cancer Cells
Author Information
Author(s): Androutsopoulos Vasilis, Arroo Randolph RJ, Hall John F, Surichan Somchaiya, Potter Gerry A
Primary Institution: Leicester School of Pharmacy, De Montfort University
Hypothesis
The study aimed to identify a possible mechanism of action for the antiproliferative effect of eupatorin, attributed to CYP1 family-mediated metabolism.
Conclusion
Eupatorin selectively inhibits breast cancer cell growth through CYP1-mediated metabolism, making it a promising candidate for chemoprevention.
Supporting Evidence
- Eupatorin showed a dose-dependent inhibitory effect on MDA-MB-468 cells.
- The IC50 for eupatorin in MDA-MB-468 cells was 0.5 μM, while in MCF-10A cells it was 50 μM.
- Eupatorin was metabolized by CYP1 enzymes to cirsiliol and other metabolites.
- CYP1A1 expression was primarily responsible for the antiproliferative effect in MDA-MB-468 cells.
- Eupatorin caused G2/M phase arrest in MDA-MB-468 cells.
Takeaway
Eupatorin is a natural compound that helps stop breast cancer cells from growing, but it doesn't harm normal breast cells.
Methodology
The study examined eupatorin's effects on MDA-MB-468 breast cancer cells and MCF-10A normal cells, assessing cytotoxicity, cell cycle effects, and metabolism by CYP1 enzymes.
Limitations
The study primarily focused on in vitro assays, and further in vivo studies are needed to confirm the findings.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website